The Europe Extracorporeal CO2 Removal Devices Market would witness market growth of 7.1% CAGR during the forecast period (2023-2030).
Extracorporeal CO2 removal (ECCO2R) devices have various applications in critical care medicine and respiratory therapy. These devices are primarily used to remove excess carbon dioxide (CO2) from the bloodstream when the lungs are unable to perform this function adequately. ECCO2R is an adjunct therapy in patients with acute respiratory failure, such as acute respiratory distress syndrome (ARDS), severe pneumonia, or chronic obstructive pulmonary disease (COPD) exacerbations.
It can help reduce elevated levels of CO2, which can be life-threatening. ECCO2R is sometimes employed to provide "lung rest" for patients with severely compromised lungs. By removing CO2, the lungs can be given a break from the work of ventilating, which may help reduce the risk of further lung damage caused by mechanical ventilation.
Moreover, these Devices can serve as a bridge to recovery for patients with reversible lung injury or disease. Providing temporary CO2 removal support allows the patient's lungs to heal and regain function while minimizing the risks associated with aggressive mechanical ventilation. They can be used during high-risk surgical procedures, such as lung transplantation or major cardiac surgery, to support patients who may not tolerate the stress of traditional ventilation strategies.
Some European cities experience high levels of air pollution due to traffic congestion and industrial activity. Prolonged exposure to air pollutants can exacerbate respiratory conditions and contribute to the development of COPD. Specific occupational environments in Europe may expose workers to harmful airborne substances, such as dust, fumes, and chemicals, which can increase the risk of COPD. In certain regions of Europe, particularly in rural areas, the use of biomass fuels for heating and cooking is common. Inhalation of indoor air pollution from burning biomass can contribute to respiratory diseases, including COPD. Hence, all of these factors are propelling the expansion of the regional market.
The Germany market dominated the Europe Extracorporeal CO2 Removal Devices Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $8,820.3 Thousands by 2030. The UK market would experience a CAGR of 6.1% during (2023 - 2030). Additionally, The France market is exhibiting a CAGR of 7.8% during (2023 - 2030).
Based on Application, the market is segmented into Bridge to Lung Transplant, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and Others. Based on End-Use, the market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, and Others. Based on Product, the market is segmented into Extracorporeal CO2 Machines, Disposables, and Others. Based on Access, the market is segmented into Arteriovenous & Venovenous. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Extracorporeal CO2 Removal Devices Market will Hit $132.8 Million by 2030, at a CAGR of 7.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Getinge AB, Fresenius Medical Care AG & Co. KGaA , Medica S.P.A., Aferetica srl, LivaNova PLC, ESTOR S.P.A., X-COR Therapeutics
By Application
By End-Use
By Product
By Access
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
